DG
RNAM

David Goel’s Avidity Biosciences RNAM Stock Holding History

David Goel’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,200,000
Closed -$29.7M – 25
2021
Q2 		$29.7M Hold
1,200,000
– – 0.32% 23
2021
Q1 		$26.2M Hold
1,200,000
– – 0.3% 28
2020
Q4 		$30.6M Hold
1,200,000
– – 0.33% 28
2020
Q3 		$33.8M Hold
1,200,000
– – 0.45% 25
2020
Q2 		$33.9M Buy
+1,200,000
New +$34.6M 0.53% 23

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Goel's RNAM Position: Q3 2021 in Review

David Goel sold out of Avidity Biosciences (RNAM) in Q3 2021, closing a stake of 1,200,000 shares — an estimated $29.7M sold.

David Goel first reported a position in RNAM in Q2 2020 and held it in 5 quarters. The position peaked at $33.9M in Q2 2020. 111 funds tracked by Wall St. Rank hold RNAM as of Q3 2021.

  • David Goel reported no remaining Avidity Biosciences position as of Q3 2021 after selling out during the quarter.
  • David Goel sold 1,200,000 Avidity Biosciences shares in Q3 2021, an estimated $29.7M.
  • David Goel first reported a position in Avidity Biosciences in Q2 2020 and held it in 5 quarters.
  • David Goel's Avidity Biosciences position peaked at $33.9M in Q2 2020.
  • 111 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2021.

Based on Matrix Capital Management Company's 13F filing for Q3 2021, filed 15 Nov 2021.